CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.
dc.contributor.author | Hu, Shimin | |
dc.contributor.author | Xu-Monette, Zijun Y | |
dc.contributor.author | Balasubramanyam, Aarthi | |
dc.contributor.author | Manyam, Ganiraju C | |
dc.contributor.author | Visco, Carlo | |
dc.contributor.author | Tzankov, Alexander | |
dc.contributor.author | Liu, Wei-min | |
dc.contributor.author | Miranda, Roberto N | |
dc.contributor.author | Zhang, Li | |
dc.contributor.author | Montes-Moreno, Santiago | |
dc.contributor.author | Dybkær, Karen | |
dc.contributor.author | Chiu, April | |
dc.contributor.author | Orazi, Attilio | |
dc.contributor.author | Zu, Youli | |
dc.contributor.author | Bhagat, Govind | |
dc.contributor.author | Richards, Kristy L | |
dc.contributor.author | Hsi, Eric D | |
dc.contributor.author | Choi, William WL | |
dc.contributor.author | Han van Krieken, J | |
dc.contributor.author | Huang, Qin | |
dc.contributor.author | Huh, Jooryung | |
dc.contributor.author | Ai, Weiyun | |
dc.contributor.author | Ponzoni, Maurilio | |
dc.contributor.author | Ferreri, Andrés JM | |
dc.contributor.author | Zhao, Xiaoying | |
dc.contributor.author | Winter, Jane N | |
dc.contributor.author | Zhang, Mingzhi | |
dc.contributor.author | Li, Ling | |
dc.contributor.author | Møller, Michael B | |
dc.contributor.author | Piris, Miguel A | |
dc.contributor.author | Li, Yong | |
dc.contributor.author | Go, Ronald S | |
dc.contributor.author | Wu, Lin | |
dc.contributor.author | Medeiros, L Jeffrey | |
dc.contributor.author | Young, Ken H | |
dc.date.accessioned | 2019-09-21T21:08:55Z | |
dc.date.available | 2019-09-21T21:08:55Z | |
dc.date.issued | 2013-04 | |
dc.date.updated | 2019-09-21T21:08:54Z | |
dc.description.abstract | CD30, originally identified as a cell-surface marker of Reed-Sternberg and Hodgkin cells of classical Hodgkin lymphoma, is also expressed by several types of non-Hodgkin lymphoma, including a subset of diffuse large B-cell lymphoma (DLBCL). However, the prognostic and biological importance of CD30 expression in DLBCL is unknown. Here we report that CD30 expression is a favorable prognostic factor in a cohort of 903 de novo DLBCL patients. CD30 was expressed in ∼14% of DLBCL patients. Patients with CD30(+) DLBCL had superior 5-year overall survival (CD30(+), 79% vs CD30(-), 59%; P = .001) and progression-free survival (P = .003). The favorable outcome of CD30 expression was maintained in both the germinal center B-cell and activated B-cell subtypes. Gene expression profiling revealed the upregulation of genes encoding negative regulators of nuclear factor κB activation and lymphocyte survival, and downregulation of genes encoding B-cell receptor signaling and proliferation, as well as prominent cytokine and stromal signatures in CD30(+) DLBCL patients, suggesting a distinct molecular basis for its favorable outcome. Given the superior prognostic value, unique gene expression signature, and significant value of CD30 as a therapeutic target for brentuximab vedotin in ongoing successful clinical trials, it seems appropriate to consider CD30(+) DLBCL as a distinct subgroup of DLBCL. | |
dc.identifier | blood-2012-10-461848 | |
dc.identifier.issn | 0006-4971 | |
dc.identifier.issn | 1528-0020 | |
dc.identifier.uri | ||
dc.language | eng | |
dc.publisher | American Society of Hematology | |
dc.relation.ispartof | Blood | |
dc.relation.isversionof | 10.1182/blood-2012-10-461848 | |
dc.subject | Humans | |
dc.subject | Cyclophosphamide | |
dc.subject | Vincristine | |
dc.subject | Doxorubicin | |
dc.subject | Prednisone | |
dc.subject | Antigens, CD30 | |
dc.subject | Antineoplastic Agents | |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject | Prognosis | |
dc.subject | Disease-Free Survival | |
dc.subject | Treatment Outcome | |
dc.subject | Multivariate Analysis | |
dc.subject | Survival Analysis | |
dc.subject | Follow-Up Studies | |
dc.subject | Gene Expression Regulation, Neoplastic | |
dc.subject | Middle Aged | |
dc.subject | Female | |
dc.subject | Male | |
dc.subject | Lymphoma, Large B-Cell, Diffuse | |
dc.subject | Antibodies, Monoclonal, Murine-Derived | |
dc.subject | Transcriptome | |
dc.subject | Rituximab | |
dc.title | CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. | |
dc.type | Journal article | |
duke.contributor.orcid | Xu-Monette, Zijun Y|0000-0002-7615-3949 | |
duke.contributor.orcid | Young, Ken H|0000-0002-5755-8932 | |
pubs.begin-page | 2715 | |
pubs.end-page | 2724 | |
pubs.issue | 14 | |
pubs.organisational-group | School of Medicine | |
pubs.organisational-group | Duke | |
pubs.organisational-group | Pathology | |
pubs.organisational-group | Clinical Science Departments | |
pubs.publication-status | Published | |
pubs.volume | 121 |